# US 2019/0167753 A1 · A subcutaneous injection formulation for reducing body weight and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0167753 A1
- Document ID: US20190167753A1
- Status: Published application
- Kind: A1
- Application number: 16/327,466
- Filed: 2017-08-25
- Published: 2019-06-06
- Earliest claimed: 2016-08-26
- Assignees: Caliway Biopharmaceuticals Co., Ltd.
- Applicants: Caliway Biopharmaceuticals Co., Ltd.
- Inventors: YU-FANG LING
- Web page: https://patentgrep.com/patent/US20190167753A1

## CPC

- A61K 36/9066: Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
- A61K 8/11: Encapsulated compositions
- A61K 8/347: {Phenols}
- A61K 8/86: Polyethers
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 9/107: Emulsions {; Emulsion preconcentrates; Micelles (composition of emulsions A61K47/00)}
- A61K 9/1075: {Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers (A61K9/0026 takes precedence)}
- A61K 31/05: Phenols {(cannabinoids A61K31/658)}
- A61K 31/12: Ketones
- A61K 31/353: 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K 36/82: Theaceae (Tea family), e.g. camellia
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/44: Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin (synthetic glycerides, e.g. medium-chain triglycerides, A61K47/14)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61Q 19/06: for countering cellulitis
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61Q: SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS

## Abstract

The present invention provides a subcutaneous injection formulation for reducing body weight. The subcutaneous injection formulation for reducing body weight comprises drug-containing micelles made of a polyoxyethylene castor oil derivative or polyoxyethylene castor oil derivatives, and a curcuminoid or curcuminoids encapsulated in the drug-containing micelles. The subcutaneous injection formulation for reducing body weight can reduce body weight and visceral fat on overweight or obese subjects, and has the advantages of low dosage, high stability, high fat tissue bioavailability, few side effects, and sustained release.

## Claims

### Claim 1

A method of reducing the body weight of an overweight or obese subject, comprising administering a subcutaneous injection formulation to the overweight or obese subject, wherein, the subcutaneous injection formulation comprising:
a curcuminoid or curcuminoids;
a pharmaceutically acceptable polyoxyethylene castor oil derivative, wherein, a hydrophilic-lipophilic balance value (HLB value) of the pharmaceutically acceptable polyoxyethylene castor oil derivative is greater than 10; and
a pharmaceutically acceptable aqueous solution;
the pharmaceutically acceptable polyoxyethylene castor oil derivative and the curcuminoid or curcuminoids together form a plurality of curcuminoid-containing micelles; the curcuminoid-containing micelles are evenly distributed in the pharmaceutically acceptable aqueous solution;
wherein, a total concentration of the curcuminoid or curcuminoids in the curcuminoid-containing micelles is 0.2 to 167 mg/g.

### Claim 2 (depends on 1)

The method of claim 1, wherein the pharmaceutically acceptable aqueous solution further comprises a catechins ingredient.

### Claim 3 (depends on 1)

The method of claim 1, wherein, the total concentration of the curcuminoid or curcuminoids in the curcuminoid-containing micelles is 0.4 to 167 mg/g; or, the total concentration of the curcuminoid or curcuminoids in the curcuminoid-containing micelles is 0.5 to 111 mg/g; or, the total concentration of the curcuminoid or curcuminoids in the curcuminoid-containing is 2 to 91 mg/g.

### Claim 4 (depends on 2)

The method of claim 2, wherein, a concentration of the catechins ingredient is 0.04 to 835 mg/g.

### Claim 5 (depends on 4)

The method of claim 4, wherein, the concentration of the catechins ingredient is 0.15 to 733 mg/g.

### Claim 6 (depends on 2)

The method of claim 2, wherein the catechins ingredient is at least one of epigallocatechin gallate, epicatechin, epicatechin gallate, epigallocatechin, gallocatechin gallate, gallocatechin, catechin gallate, and catechin, or a combination thereof.

### Claim 7 (depends on 2)

The method of claim 2, wherein a weight ratio of the curcuminoid or curcuminoids to the catechins ingredient in the subcutaneous injection formulation is 50:1 to 1:20.

### Claim 8 (depends on 7)

The method of claim 7, wherein, the weight ratio of the curcuminoid or curcuminoids to the catechins ingredient in the subcutaneous injection formulation is 30:1 to 1:10; or, the weight ratio of the curcuminoid or curcuminoids to the catechins ingredient in the subcutaneous injection formulation is 10:1 to 1:4; or, the weight ratio of the curcuminoid or curcuminoids to the catechins ingredient in the subcutaneous injection formulation is 7:1 to 1:4.

### Claim 9 (depends on 1)

The method of claim 1, wherein an administration dosage of the subcutaneous injection formulation is 0.15 to 40 milligram per kilogram for injection.

### Claim 10 (depends on 9)

The method of claim 9, wherein the administration dosage of the subcutaneous injection formulation is 0.25 to 25 milligram per kilogram for injection.

### Claim 11 (depends on 1)

The method of claim 1, wherein an administration frequency of the subcutaneous injection formulation at an administration site of the subject is 1 to 6 times every 1 to 90 days.

### Claim 12 (depends on 1)

The method of claim 1, wherein, a weight ratio of the curcuminoid or curcuminoids to the polyoxyethylene castor oil derivative is 1:5 to 1:750.

### Claim 13 (depends on 1)

The method of claim 1, wherein the polyoxyethylene castor oil derivative is at least one of Cremophor ELP, Cremophor RH 40, and other polyoxyethylene castor oil derivatives, or a combination thereof.

### Claim 14 (depends on 1)

The method of claim 1, wherein the subcutaneous injection formulation further comprises at least one of a cosolvent, a suspending agent, and an oil phase excipient, or a combination thereof.

### Claim 15 (depends on 14)

The method of claim 14, wherein the microstructure of the curcuminoid-containing micelle is collectively formed from the polyoxyethylene castor oil derivative and at least one of the oil phase excipient and the cosolvent.

### Claim 16 (depends on 1)

The method of claim 1, wherein the curcuminoid is curcumin.

### Claim 17

A method of reducing body weight of an overweight or obese subject, comprising administering a subcutaneous injection formulation to the overweight or obese subject, wherein, the subcutaneous injection formulation comprises:
a curcuminoid or curcuminoids;
resveratrol;
a pharmaceutically acceptable polyoxyethylene castor oil derivative; a hydrophilic-lipophilic balance value (HLB value) of the pharmaceutically acceptable polyoxyethylene castor oil derivative is greater than 10; and
a pharmaceutically acceptable surfactant;
the pharmaceutically acceptable polyoxyethylene castor oil derivative and the curcuminoid or curcuminoids together form a plurality of curcuminoid-containing micelles; and the pharmaceutically acceptable surfactant and the resveratrol together form a plurality of resveratrol-containing micelles;
wherein, a total concentration of the curcuminoid or curcuminoids encapsulated in the curcuminoid-containing micelles is 0.2 to 167 mg/g.

### Claim 18 (depends on 17)

The method of claim 17, wherein, a total concentration of the resveratrol encapsulated in the resveratrol-containing micelles is 0.2 to 733 mg/g.

### Claim 19

A sum of the total concentration of the curcuminoid or curcuminoids encapsulated in the curcuminoid-containing micelles and a total concentration of the resveratrol encapsulated in the resveratrol-containing micelles is 0.4 to 900 mg/g.

### Claim 20

A ratio of a total weight of the curcuminoid or curcuminoids encapsulated in the curcuminoid-containing micelles to a total weight of the resveratrol encapsulated in the resveratrol-containing micelles is 50:1 to 1:30.

### Claim 21

The ratio of the total weight of the curcuminoid or curcuminoids encapsulated in the curcuminoid-containing micelles to the total weight of the resveratrol encapsulated in the resveratrol-containing micelles is 20:1 to 1:20.

### Claim 22 (depends on 17)

The method of claim 17, wherein an administration dosage of the subcutaneous injection formulation is 0.15 to 40 milligram per kilogram for injection.

### Claim 23 (depends on 17)

The method of claim 17, wherein an administration dosage of the subcutaneous injection formulation is 0.25 to 25 milligram per kilogram for injection.

### Claim 24 (depends on 17)

The method of claim 17, wherein an administration frequency of the subcutaneous injection formulation at an administration site of the subject is 1 to 6 times every 1 to 90 days.

### Claim 25 (depends on 17)

The method of claim 17, wherein, a ratio of a total weight of the curcuminoid or curcuminoids encapsulated in the curcuminoid-containing micelles to a total weight of the polyoxyethylene castor oil derivative is 1:5 to 1:750.

### Claim 26 (depends on 17)

The method of claim 17, wherein the subcutaneous injection formulation further comprises at least one of a cosolvent, a suspending agent, and an oil phase excipient, or a combination thereof.

### Claim 27 (depends on 26)

The method of claim 26, wherein the microstructure of the curcuminoid-containing micelle is collectively formed from the polyoxyethylene castor oil derivative and at least one of the oil phase excipient and the cosolvent.

### Claim 28 (depends on 17)

The method of claim 17, wherein the pharmaceutically acceptable surfactant is a pharmaceutically acceptable second polyoxyethylene castor oil derivative, and a hydrophilic-lipophilic balance value (HLB value) of the second polyoxyethylene castor oil derivative is greater than 10.

### Claim 29 (depends on 17)

The method of claim 17, wherein, the polyoxyethylene castor oil derivative is at least one of Cremophor ELP, Cremophor RH 40, and other polyoxyethylene castor oil derivatives, or a combination thereof.

### Claim 30 (depends on 17)

The method of claim 17, wherein the curcuminoid is curcumin.

### Claim 31 (depends on 28)

The method of claim 28, wherein, the second polyoxyethylene castor oil derivative is at least one of Cremophor ELP, Cremophor RH 40, and other polyoxyethylene castor oil derivatives, or a combination thereof.